the aid library

LIST OPTIONS

Filter

11273

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (909)

View PDF (1253)

Ghana National Health Insurance Scheme Improving Financial Sustainability Based on Expenditure Review

Huihui Wang, Nathaniel Otoo, and Lydia Dsane-Selby World Bank Group (2017) C1

Download (560)

View PDF (492)

HIV and AIDS in India

Avert (2018) C2

Download (400)

View PDF (561)

Child labour report 2017 - The Neglected Link: effects of climate change and environmental degradation on child labour

Lisa Myers, Laura Theytaz-Bergman Terre des hommes (2017) C1

Over half a billion children are living in areas with extremely high levels of floods and nearly 160 million children live in areas of high or extremely high droughts. The World Health Organisation (WHO) estimates that 26% of the annual 6.6 million deaths of children under five are linked to environ... more

Download (441)

View PDF (501)

Key political commitment documents for tuberculosis prevention and care and their intended influence in the WHO European Region

World Health Organization WHO, Regional Office for Europe (2019) C_WHO

This analytical report reviews and discusses the potential role and influence of political commitment in implementing endorsements and conducting policy in the field of tuberculosis (TB) prevention and care. It promotes discussion by comparing and analysing the extent to which selected international... more

Download (286)

View PDF (346)

Treat as One. Bridging the gap between mental and physical healthcare in general hospitals

National Confidential Enquiry into Patient Outcome and Death (2017) C1

This NCEPOD report highlights the quality of mental health and physical health care for patients aged 18 years or older with a significant mental disorder who are admitted to a general hospital. The report takes a critical look at areas where the care of patients might have been improved. Remediable... more

Download (529)

View PDF (834)

Guidelines on second-and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus

World Health Organization WHO (2018) C_WHO

The new guidelines provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings. These guidelines update the recommendations for managing hyperglycaemia in the WHO Package of Essential NCD I... more

Download (1126)

View PDF (2412)

Technical note for Ebola virus disease preparedness planning for entry screening at airports, ports and land crossings

World Health Organization (2014)

Download (744)

View PDF (680)

Global Tuberculosis Report 2021
recommended

World Health Organization WHO (2021) C_WHO

Each year, the WHO Global TB Report provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets. The... more

Download (286)

View PDF (405)

Interim Infection Prevention and Control Recommendations for Coronavirus Disease 2019 (COVID-19) in Health Care Settings

Ministry of Health, Kenya (2020) C2

Accessed: 02.05.2020 These interim IPC recommendations for health settings have been developed through the contributions of many individuals and institutions, such as the Centers for Disease Control-Kenya; ITECH; US Agency for International Development (USAID) Medicines, Technologies, and Pharmaceu... more

Download (284)

View PDF (450)

Monkeypox: Current status in West and Central Africa

World Health Organization (WHO) (2018) C_WHO

Monkeypox is an emerging viral zoonosis with symptoms similar to those observed in smallpox patients, although less severe. Since the global eradication of smallpox in 1980, monkeypox has emerged as the most important orthopoxvirus in humans. The Advisory Committee on Variola Virus Research (ACVVR) ... more

Download (375)

View PDF (813)

Ökonomische Bewertung in der globalen Gesundheit

Kohler, S.; N.Paul, T. Bärnighausen, P. Geldsetzer (2021) CC

In: Bonk M., Ulrichs T. (eds). Global Health: Das Konzept der Globalen Gesundheit. Berlin: De Gruyter, 2021, pp. 557–580

Download (290)

View PDF (424)

Redefining the Antibiotic Stewardship Team

Centers for Disease Control and Prevention CDC, American Nurses Association ANA (2017) C_CDC

Recommendations from the American Nurses Association/Centers for Disease Control and Prevention Workgroup on the Role of Registered Nurses in Hospital Antibiotic Stewardship Practices

Download (354)

View PDF (373)

Evaluation of COVID-19 vaccine effectiveness in a changing landscape of COVID-19 epidemiology and vaccination

World Health Organization WHO (2022) C_WHO

Interim Guidance October 2022. This addendum addresses some of the methodological aspects of VE evaluations that have been learned during the past year, as well as those that have become relevant in the current epidemiological setting of the COVID-19 pandemic. For some of the COVID-19 vaccine method... more

Download (353)

View PDF (540)

Kairos for Creation - Confession Hope for Earth

Andrianos, L.; M.Biehl, R. Gütter ,et al. Brot für die Welt; WCC; EKD; et al. (2019) CC

The “Wuppertal Call” – Contributions and Recommendations from an International Conference on Eco-Theology and Ethics of Sustainability Wuppertal, Germany, 16 – 19 June 2019

Download (379)

View PDF (348)

Centering communities in pandemic preparedness and response

The Independent Panel (2021) CC

Background paper 10 The Independent Panel for Pandemic Preparedness and Response May 2021

Download (517)

View PDF (567)

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Policy brief
recommended

World Health Organization WHO (2022) C_WHO

Cryptococcal disease, particularly cryptococcal meningitis is a significant cause of morbidity and mortality among people living with HIV with advanced HIV disease. It is estimated that it is responsible for nearly 19% of AIDS-related mortality, second only to tuberculosis. Rapid screening, diagnosi... more

Download (367)

View PDF (544)

Regional Emergency Response Appeal for the Greater Horn of Africa

World Health Organization WHO (2022) CC

The Greater Horn of Africa is experiencing one of the worst food insecurity situations in decades. It is estimated that more than 37 million people are in Integrated Food Security Phase Classification (IPC)1 phase 3 or above and approximately 7 million children under the age of five are acutely mal... more

Download (313)

View PDF (465)

Tsetse Control and Gambian Sleeping Sickness; Implications for Control Strategy

Tirados, I.; Esterhuizen, J.; Kovacic, V.; Mangwiro, TNC.; Vale, GA et al. PLOS Neglected Tropical Diseases (2015) CC

Sleeping sickness is controlled by case detection and treatment but this often only reaches less than 75% of the population. Vector control is capable of completely interrupting HAT transmission but is not used because of expense. We conducted a full scale field trial of a refined vector control tec... more

Global Tuberculosis Report 2021 recommended

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Policy brief recommended

Global Tuberculosis Report 2021
recommended

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Policy brief
recommended